Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 461

1.

Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents.

Wiley JL, Walentiny DM, Wright MJ Jr, Beardsley PM, Burston JJ, Poklis JL, Lichtman AH, Vann RE.

Eur J Pharmacol. 2014 Aug 15;737:97-105. doi: 10.1016/j.ejphar.2014.05.013. Epub 2014 May 22.

2.

Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.

Walentiny DM, Vann RE, Wiley JL.

Neuropharmacology. 2015 Jun;93:237-42. doi: 10.1016/j.neuropharm.2015.02.004. Epub 2015 Feb 16.

3.

Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB1 receptor-mediated discriminative stimulus in mice.

Owens RA, Mustafa MA, Ignatowska-Jankowska BM, Damaj MI, Beardsley PM, Wiley JL, Niphakis MJ, Cravatt BF, Lichtman AH.

Neuropharmacology. 2017 Oct;125:80-86. doi: 10.1016/j.neuropharm.2017.06.032. Epub 2017 Jun 30.

4.

Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ9-tetrahydrocannabinol in mice.

Hruba L, Seillier A, Zaki A, Cravatt BF, Lichtman AH, Giuffrida A, McMahon LR.

J Pharmacol Exp Ther. 2015 May;353(2):261-8. doi: 10.1124/jpet.115.222836. Epub 2015 Feb 24.

5.

The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.

Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, Vadivel SK, Makriyannis A, Goldberg SR.

J Pharmacol Exp Ther. 2007 Apr;321(1):370-80. Epub 2007 Jan 8.

7.

Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Wiebelhaus JM, Grim TW, Owens RA, Lazenka MF, Sim-Selley LJ, Abdullah RA, Niphakis MJ, Vann RE, Cravatt BF, Wiley JL, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2015 Feb;352(2):195-207. doi: 10.1124/jpet.114.218677. Epub 2014 Nov 14.

8.

Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.

Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, Cravatt BF.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20270-5. doi: 10.1073/pnas.0909411106. Epub 2009 Nov 16.

9.

Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D(2)-induced formation of anandamide.

Solinas M, Tanda G, Wertheim CE, Goldberg SR.

Psychopharmacology (Berl). 2010 Apr;209(2):191-202. doi: 10.1007/s00213-010-1789-8. Epub 2010 Feb 24.

10.

Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.

Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH.

Pharmacol Biochem Behav. 2011 Mar;98(1):21-7. doi: 10.1016/j.pbb.2010.12.002. Epub 2010 Dec 8.

11.

Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.

Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2009 Sep;330(3):902-10. doi: 10.1124/jpet.109.155465. Epub 2009 Jun 5.

12.

Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice.

Owens RA, Ignatowska-Jankowska B, Mustafa M, Beardsley PM, Wiley JL, Jali A, Selley DE, Niphakis MJ, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2016 Aug;358(2):306-14. doi: 10.1124/jpet.115.229492. Epub 2016 Jun 15.

13.

Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide.

Solinas M, Scherma M, Tanda G, Wertheim CE, Fratta W, Goldberg SR.

J Pharmacol Exp Ther. 2007 Jun;321(3):1127-34. Epub 2007 Mar 9.

PMID:
17351107
14.

Just add water: cannabinoid discrimination in a water T-maze with FAAH(-/-) and FAAH(+/+) mice.

Wiley JL, Lefever TW, Pulley NS, Marusich JA, Cravatt BF, Lichtman AH.

Behav Pharmacol. 2016 Aug;27(5):479-84. doi: 10.1097/FBP.0000000000000228.

15.

Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats.

Panlilio LV, Thorndike EB, Nikas SP, Alapafuja SO, Bandiera T, Cravatt BF, Makriyannis A, Piomelli D, Goldberg SR, Justinova Z.

Psychopharmacology (Berl). 2016 May;233(10):1879-88. doi: 10.1007/s00213-015-4140-6. Epub 2015 Nov 12.

16.

Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice.

Wise LE, Long KA, Abdullah RA, Long JZ, Cravatt BF, Lichtman AH.

ACS Chem Neurosci. 2012 May 16;3(5):369-78. doi: 10.1021/cn200130s. Epub 2012 Jan 27.

17.

Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain.

Guindon J, Guijarro A, Piomelli D, Hohmann AG.

Br J Pharmacol. 2011 Aug;163(7):1464-78. doi: 10.1111/j.1476-5381.2010.01192.x.

18.

Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.

Schlosburg JE, Carlson BL, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, Lichtman AH.

AAPS J. 2009 Jun;11(2):342-52. doi: 10.1208/s12248-009-9110-7. Epub 2009 May 9.

19.

The role of CB1 in intestinal permeability and inflammation.

Karwad MA, Couch DG, Theophilidou E, Sarmad S, Barrett DA, Larvin M, Wright KL, Lund JN, O'Sullivan SE.

FASEB J. 2017 Aug;31(8):3267-3277. doi: 10.1096/fj.201601346R. Epub 2017 Apr 12.

PMID:
28404744
20.

Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.

Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, King AR, Redhi GH, Yasar S, Piomelli D, Goldberg SR.

Biol Psychiatry. 2008 Dec 1;64(11):930-7. doi: 10.1016/j.biopsych.2008.08.008. Epub 2008 Sep 23.

Supplemental Content

Support Center